Key result
Spironolactone, MRAs, and renal denervation emerge as promising treatments for resistant hypertension.
Why the study?
Despite available pharmacological therapies, achieving optimal blood pressure control in resistant hypertension remains a challenge, while promising new treatment options and personalized management approaches have emerged.
Resistant hypertension is a complex, multifactorial condition requiring careful exclusion of pseudo-resistance and personalized management strategies addressing underlying pathophysiological and lifestyle factors.
May inform personalized resistant hypertension care; leaves open the need for RCTs confirming comparative efficacy of listed options.
Resistant hypertension, defined as blood pressure that remains above goal despite using three or more antihypertensive medications, including a diuretic, affects a significant proportion of the hypertensive population and is associated with increased cardiovascular morbidity and mortality. Despite the availability of a wide range of pharmacological therapies, achieving optimal blood pressure control in patients with resistant hypertension remains a significant challenge. However, recent advances in the field have identified several promising treatment options, including spironolactone, mineralocorticoid receptor antagonists, and renal denervation. In addition, personalized management approaches based on genetic and other biomarkers may offer new opportunities to tailor therapy and improve outcomes. This review aims to provide an overview of the current state of knowledge regarding managing resistant hypertension, including the epidemiology, pathophysiology, and clinical implications of the condition, as well as the latest developments in therapeutic strategies and future prospects.
No takes yet. Share an insight, caveat, or question.
Champaneria et al. (2023) conducted a review in Resistant hypertension. Spironolactone, mineralocorticoid receptor antagonists, and renal denervation was evaluated. Recent advances in managing resistant hypertension include promising treatment options such as spironolactone, mineralocorticoid receptor antagonists, renal denervation, and personalized approaches.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: